Jounce Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
141
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$96.5M
Jounce Therapeutics General Information
Description
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.
Contact Information
Website
www.jouncetx.comCorporate Office
- 780 Memorial Drive
- Cambridge, MA 02139
- United States
Corporate Office
- 780 Memorial Drive
- Cambridge, MA 02139
- United States
Jounce Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 03-May-2023 | $96.5M | Completed | Generating Revenue | ||
| 8. Merger/Acquisition | 27-Mar-2023 | Cancelled | Generating Revenue | |||
| 7. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 6. Merger/Acquisition | 09-Apr-2018 | Cancelled | Generating Revenue | |||
| 5. 2PO | 22-Jun-2017 | Completed | Generating Revenue | |||
| 4. IPO | 27-Jan-2017 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B1) | 19-Jul-2016 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 17-Apr-2015 | $56M | $103M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 14-Feb-2013 | $47M | $47M | Completed | Startup |
Jounce Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 47,000,000 | $0.001000 | $0.08 | $1 | $1 | 1x | $1 | 45.02% |
Jounce Therapeutics Comparisons
Industry
Financing
Details
Jounce Therapeutics Competitors (4)
One of Jounce Therapeutics’s 4 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| Perthera | Venture Capital-Backed | McLean, VA |
Jounce Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Jounce Therapeutics Patents
Jounce Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220289847-A1 | Methods for the treatment of cancer | Inactive | 09-Mar-2021 | ||
| CA-3213110-A1 | Methods for the treatment of cancer | Pending | 09-Mar-2021 | ||
| AU-2022234761-A1 | Methods for the treatment of cancer | Pending | 09-Mar-2021 | ||
| AU-2022234761-A9 | Methods for the treatment of cancer | Pending | 09-Mar-2021 | ||
| EP-4304648-A1 | Methods for the treatment of cancer | Inactive | 09-Mar-2021 | A61P35/00 |
Jounce Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jounce Therapeutics Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Casdin Capital | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Fidelity Investments | Mutual Fund | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| Life sciences investment group | Corporation |
Jounce Therapeutics ESG
Risk Overview
Risk Rating
Updated August, 08, 2023
28.28 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Biotechnology
Subindustry
of 402
Rank
Percentile
Jounce Therapeutics FAQs
-
When was Jounce Therapeutics founded?
Jounce Therapeutics was founded in 2013.
-
Where is Jounce Therapeutics headquartered?
Jounce Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Jounce Therapeutics?
Jounce Therapeutics has 141 total employees.
-
What industry is Jounce Therapeutics in?
Jounce Therapeutics’s primary industry is Biotechnology.
-
Is Jounce Therapeutics a private or public company?
Jounce Therapeutics is a Private company.
-
What is the current valuation of Jounce Therapeutics?
The current valuation of Jounce Therapeutics is .
-
What is Jounce Therapeutics’s current revenue?
The current revenue for Jounce Therapeutics is .
-
How much funding has Jounce Therapeutics raised over time?
Jounce Therapeutics has raised $241M.
-
Who are Jounce Therapeutics’s investors?
Casdin Capital, Cormorant Asset Management, Fidelity Investments, Foresite Capital, and Life sciences investment group are 5 of 12 investors who have invested in Jounce Therapeutics.
-
Who are Jounce Therapeutics’s competitors?
NexImmune, Aura Biosciences, Bluebird Bio, and Perthera are competitors of Jounce Therapeutics.
-
When was Jounce Therapeutics acquired?
Jounce Therapeutics was acquired on 03-May-2023.
-
Who acquired Jounce Therapeutics?
Jounce Therapeutics was acquired by Concentra Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
